摘要
目的探讨丹参注射液联合侧脑室外引流救治急性重型原发性颅脑损伤的效果。方法选取我院2013年7月-2014年7月的68例急性重型原发性颅脑损伤患者为研究对象,将其随机分为对照组和观察组。对照组患者使用丹参注射液进行治疗,观察组患者采用丹参注射液联合侧脑室外引流进行治疗。观察2组患者在治疗前、治疗后3d以及1周行格拉斯哥昏迷评分(GCS)以及临床疗效和血肿清除时间。结果治疗前,2组患者的GCS评分无明显差异;治疗3d后观察组GCS评分明显高于对照组;1周后的效果达到最佳(P〈0.05)。对照组与观察组治疗的总有效率分别为70.59%和88.24%,观察组的有效率明显高于对照组(P〈0.05);对照组与观察组的平均消除时间分别为10.0±4.5和4.0±2.5d,观察组血肿的平均消除时间明显低于对照组(P〈0.05)。结论丹参注射液联合侧脑室外引流救治急性重型原发性颅脑损伤患者能提高患者的总有效率,缩短患者的持续昏迷时间,改善患者的预后情况。
Objective To study the effect of Danshen Injections combined with lateral ventricle external drainage in the treatment of acute severe primary craniocerebral injury .Methods 68 cases of acute severe patients with primary brain injury in our hospital in 2013 July‐2014 July was selected as the research objects ,divided into control group and observation group .The control group were given Danshen Injections treatment ,while the observation group were treated by Danshen Injections combined with lateral cerebral ventricular drainage treatment .1 week later Glasgow coma score (GCS) ,clinical curative effect and hematoma removal time were statistically analyzed and compared .Results Before treatment ,no significant difference was observed between the 2 groups .3 days after treatment ,GCS of the observation group of GSC score was significantly higher than the control group .And 1 week after the optimal effect ;the total effective rate of treatment were 70 .59% and 88 .24% for the control group and the observation group .The observation group was obviously higher than that of the control group ,with significant difference (P〈0 .05);The mean elimina‐ting times were 10 .0 ± 4 .5 and 4 .0 ± 2 .5 d for the control group and the observation group with significant difference (P〈0 .05) . Conclusion Danshen Injections combined with lateral ventricle external drainage in the treatment of acute severe patients with pri‐mary brain injury can improve the patient's total efficiency ,shorten the time of patients with persistent coma ,improve the prognosis of patients and the quality of life .
出处
《西北药学杂志》
CAS
2015年第5期630-632,共3页
Northwest Pharmaceutical Journal